AIM ImmunoTech Expands Ampligen Patent Protection in Europe and U.K. Through 2041
OCALA, Fla., Sept. 2, 2026 AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharmaceutical company developing Ampligen® (rintatolimod), announced that...
TLR3
Advertisement
AIM ImmunoTech Wins U.S. Patent for Ampligen Cancer Therapy
OCALA, Fla., August 31, 2026 AIM ImmunoTech Inc. announced that the U.S. Patent and Trademark Office (USPTO) has granted...
AIM ImmunoTech Advances Ampligen Phase 3 Cancer Trial
OCALA, Fla., April 16, 2026 AIM ImmunoTech Inc. has announced significant progress in its oncology pipeline, entering a pivotal...
Advertisement
